20 years of Cure Parkinson's
We’re here for the cure! This year marks 20 years since Cure Parkinson’s was founded by four people living with Parkinson’s who felt that nobody was taking a cure seriously enough and that there was an urgent need for a focused approach to curative research...
Learn more
Type 2 diabetes medications impact risk of Parkinson’s
In a recent study, researchers have concluded that the elevated risk of Parkinson’s in patients with type 2 diabetes might be mitigated depending on the type of drugs prescribed to treat this type of diabetes.
The 2020 International Linked Clinical Trials meeting
The International Linked Clinical Trials (iLCT) programme is the drug repurposing initiative focussed on identifying and clinically testing drugs that show potential in slowing or reversing the progression of Parkinson’s.
The 2020 Linked Clinical Trials meeting
Each year in September, The Cure Parkinson’s Trust and Van Andel Institute hold the international Linked Clinical Trials (iLCT) meeting. This is a drug-repurposing initiative focused on disease modification in Parkinson’s. For two days the iLCT committee discuss and debate the virtues of 20+ molecules to decide which should be prioritised […]
Tom Isaacs Award winner 2020 – Professor Caroline Tanner
Cure Parkinson’s and Van Andel Institute (VAI) are delighted to announce Professor Caroline Tanner, University of California San Francisco’s Weill Institute for Neurosciences, as the winner of the 2020 Tom Isaacs Award. The award was presented at the annual Rallying to the Challenge patient meeting. Throughout…
2020 Tom Isaacs Award honours leading Parkinson’s expert
25 September 2020 The Cure Parkinson’s Trust (CPT) and Van Andel Institute (VAI) are delighted to announce Professor Caroline Tanner of University of California San Francisco’s Weill Institute for Neurosciences as this year’s deserving winner of the ‘Tom Isaacs Award’. The award was presented today…